Ontology highlight
ABSTRACT:
SUBMITTER: O'Brien SM
PROVIDER: S-EPMC6593416 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
O'Brien Susan M SM Byrd John C JC Hillmen Peter P Coutre Steven S Brown Jennifer R JR Barr Paul M PM Barrientos Jacqueline C JC Devereux Stephen S Robak Tadeusz T Reddy Nishitha M NM Kipps Thomas J TJ Tedeschi Alessandra A Cymbalista Florence F Ghia Paolo P Chang Stephen S Ninomoto Joi J James Danelle F DF Burger Jan A JA
American journal of hematology 20190308 5
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of si ...[more]